Compare Nuwellis Inc (NUWE) vs Tapestry, Inc. (TPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs Tapestry, Inc. — how do they compare? Nuwellis Inc trades at $0.69 (market cap $2.20M), while Tapestry, Inc. trades at $115.82 (market cap $22.62B). The key difference: Tapestry, Inc. is far larger — about 10281.8× Nuwellis Inc's market cap, and Tapestry, Inc. pays a 1.63% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nuwellis Inc for 26 Days and Tapestry, Inc. for 70 Days on average.
| NUWE | TPR | |
|---|---|---|
Market Cap | $2.20M | $22.62B |
Volume | 121,544 | 2,093,865 |
Sector | Health | Consumer Cyclical |
52-Week High | $146.65 | $164.78 |
52-Week Low | $0.68 | $98.81 |
Typical Hold Time | 26 Days | 70 Days |
Enterprise Value | -$1.52M | $25.42B |
Dividend Yield | — | 1.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
TPR trades at $115.82, down 0.78% today, with a bearish technical signal but strong analyst support (73% buy ratings). The company shows robust profitability with 77.82% gross margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights international growth in China and Europe, though the stock faces headwinds from tariff risks and Kate Spade execution challenges.
Outlook remains positive with a $174.64 consensus price target suggesting 51% upside, supported by fiscal 2027 margin expansion targets. Key risks include tariff pressures, premium valuation (P/E 15.6), and recent net cash outflows. The stock presents a growth opportunity if international momentum continues and margin targets are achieved.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About Tapestry, Inc.
Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →
